Trial Profile
A Phase 3, Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled Study Comparing the Safety and Efficacy of Adalimumab to Methotrexate in Subjects With Moderate to Severe Chronic Plaque Psoriasis
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 09 May 2018
Price :
$35
*
At a glance
- Drugs Adalimumab (Primary) ; Methotrexate
- Indications Plaque psoriasis
- Focus Adverse reactions; Therapeutic Use
- Acronyms CHAMPION
- Sponsors Abbott Laboratories
- 01 Jan 2018 Results comparing Adalimumab and Etanercept for the Treatment of Moderate to Severe Psoriasis in patients data from M10-114, M10-315, REVEAL and CHAMPION trials (n=1692), published in the Value in Health
- 06 Oct 2017 Results (n=273) of a post hoc retrospective analysis developing and validating a prediction rule to identify patients unlikely to respond adequately to methotrexate using patient data from NCT00235820 and NCT00679731 trials published in the Journal of the American Academy of Dermatology
- 08 Mar 2016 Pooled analysis (n=1692) of 4 trials (NCT00237887, NCT00235820, NCT00691964, NCT00710580) were presented at the 74th Annual Meeting of the American Academy of Dermatology.